1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: The ASC2ESCALATE Phase II trial
    Journal Article

    Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J. E.
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies
    Review

    Boussi, L.; Biswas, J.; Abdel-Wahab, O.; Stein, E.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors
    Journal Article

    Lenz, H. J.; Argilés, G.; de Jonge, M. J. A.; Yaeger, R.; Doi, T.; El-Khoueiry, A.; Eskens, F.; Kuboki, Y.; Bertulis, J.; Nazabadioko, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Oral minoxidil for late alopecia in cancer survivors
    Journal Article

    Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K. F.; Pan, A.; Kraehenbuehl, L.; Dusza, S.; Gajria, D.; Lake, D. E.; Bromberg, J. F.; Traina, T. A.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Emerging tumor-agnostic molecular targets
    Review

    Bhamidipati, D.; Schram, A. M.
    Molecular Cancer Therapeutics (2024)

    Fulltext@MSK | Save
  • uPAR immuno-PET in pancreatic cancer, aging, and chemotherapy-induced senescence
    Journal Article

    Pratt, E. C.; Mezzadra, R.; Kulick, A.; Kaminsky, S.; Samuels, Z. V.; Loor, A.; de Stanchina, E.; Lowe, S. W.; Lewis, J. S.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Revumenib for patients with acute leukemia: A new tool for differentiation therapy
    Review

    Yisraeli Salman, M.; Stein, E. M.
    Haematologica (2024)

    Fulltext@MSK | Save
  • Breast cancer and cardiovascular health
    Review

    López-Fernández, T.; Marco, I.; Aznar, M. C.; Barac, A.; Bergler-Klein, J.; Meattini, I.; Scott, J. M.; Cardinale, D.; Dent, S.
    European Heart Journal (2024)

    Fulltext@MSK | Save
  • The INSIGHT study: A randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations
    Journal Article

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma
    Research Letter

    Shitara, K.; Shah, M. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Kang, Y. K.; Lonardi, S.; Hung, Y. P.; Yamaguchi, K.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save